You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

refractory graft versus host disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

A PMS of Jakavi® in Steroid-Refractory Graft-versus-Host Disease

Not yet recruiting
  • Graft-versus-Host Disease
  • ruxolitinib
  • (no location specified)
Jan 11, 2023

Chronic GVHD, Steroid Refractory GVHD Trial in Duarte (Leflunomide)

Recruiting
  • Chronic Graft Versus Host Disease
  • Steroid Refractory Graft Versus Host Disease
  • Duarte, California
    City of Hope Medical Center
Sep 14, 2022

Hematopoietic and Lymphoid Cell Tumor, Steroid Refractory GVHD Trial in Houston (Cellular Therapy, Ruxolitinib)

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Steroid Refractory Graft Versus Host Disease
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Steroid-refractory Acute Graft-versus-host Disease Trial (MC0518, BAT)

Not yet recruiting
  • Steroid-refractory Acute Graft-versus-host Disease
  • MC0518
  • BAT
  • (no location specified)
Oct 4, 2023

GVHD, Acute Stem Cell Transplant Complications Trial in Chendu (Ruxolitinib)

Not yet recruiting
  • GVHD
  • Acute Stem Cell Transplant Complications
  • Chendu, Sichuan, China
    West China Hospital, Sichuan University
Oct 3, 2023

Acute GVHD, Steroid Refractory GVHD Trial in Columbus (BRD4 Inhibitor PLX51107)

Recruiting
  • Acute Graft Versus Host Disease
  • Steroid Refractory Graft Versus Host Disease
  • BRD4 Inhibitor PLX51107
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 24, 2022

Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease Trial in United States

Completed
  • Steroid-refractory Acute Graft-versus-Host Disease
  • Treatment-refractory Acute Graft-versus-Host Disease
  • Neihulizumab (ALTB-168)
  • Duarte, California
  • +12 more
Jan 17, 2023

Acute GVHD Trial in Kansas City (MSCTC-0010 Dose Escalation)

Recruiting
  • Acute Graft Versus Host Disease
  • MSCTC-0010 Dose Escalation
  • Kansas City, Kansas
    Kansas University Cancer Center
Jan 30, 2023

Chronic GVHD Trial in Duarte (biological, procedure, other)

Active, not recruiting
  • Chronic Graft Versus Host Disease
  • Aldesleukin
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

GVHD,Acute, Stem Cell Transplant Complications Trial in Chengdu (Methylprednisolone)

Recruiting
  • GVHD,Acute
  • Stem Cell Transplant Complications
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 9, 2022

Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)

Not yet recruiting
  • Chronic Graft Versus Host Disease
  • +2 more
  • Biopsy
  • +11 more
  • Duarte, California
    City of Hope Medical Center
Aug 7, 2023

Hematopoietic and Lymphoid System Tumor, Malignant Solid Tumor, Refractory Sclerodermatous GVHD Trial in Duarte (procedure,

Not yet recruiting
  • Hematopoietic and Lymphoid System Neoplasm
  • +2 more
  • Biospecimen Collection
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Aug 23, 2022

GVHD Trial in Cleveland (Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP))

Not yet recruiting
  • Graft Versus Host Disease
  • Allogeneic mesenchymal stromal cells (MSCs)
  • Extracorporeal photopheresis (ECP)
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Nov 14, 2022

Intestinal GVHD, Steroid Refractory GVHD Trial in France (Blood and stool sample collection)

Recruiting
  • Intestinal GVHD
  • Steroid Refractory GVHD
  • Blood and stool sample collection
  • Amiens, France
  • +8 more
Jun 20, 2022

Chronic GVHD Trial in Sevilla (Regulatory T-cell enriched infusion)

Recruiting
  • Chronic Graft vs Host Disease
  • Regulatory T-cell enriched infusion
  • Sevilla, Spain
    José Antonio Pérez Simón
May 20, 2022

Sclerodermoid Chronic GVHD (Disorder) Trial in Spain (Glasdegib)

Active, not recruiting
  • Sclerodermoid Chronic Graft-Versus-Host Disease (Disorder)
  • Barcelona, Spain
  • +5 more
Mar 16, 2022

Acute GVHD Trial in Zhengzhou (Jaktinib Hydrochloride Tablets)

Not yet recruiting
  • Acute Graft-Versus-Host Disease
  • Jaktinib Hydrochloride Tablets
  • Zhengzhou, Henan, China
    Henan Tumor Hospital
Nov 29, 2021

Acute GVHD Trial in Spain (Adult Allogeneic Mesenchymal cells from adipose tissue.)

Active, not recruiting
  • Acute Graft Versus Host Disease
  • Adult Allogeneic Mesenchymal cells from adipose tissue.
  • Pamplona, Navarra, Spain
  • +5 more
Feb 1, 2022

Acute-graft-versus-host Disease Trial (ASC930)

Not yet recruiting
  • Acute-graft-versus-host Disease
  • ASC930
  • (no location specified)
Nov 16, 2021

Chronic GVHD, Acute GVHD, Steroid Refractory GVHD Trial in Leuven, Liège (Rapamycin, T regulatory cells)

Recruiting
  • Chronic Graft-Versus-Host Disease
  • +2 more
  • Leuven, Vlaams-Brabant, Belgium
  • +1 more
Apr 27, 2021

Chronic GVHD Trial in Boston (Abatacept)

Active, not recruiting
  • Chronic Graft Versus Host Disease
  • Boston, Massachusetts
  • +1 more
Jan 25, 2022

GVHD Trial in Hackensack (Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose

Terminated
Has Results
  • Graft Versus Host Disease
  • Cyclophosphamide and Sirolimus
  • +3 more
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Feb 4, 2022

Acute GVHD in Intestine, Steroid Refractory GVHD Trial in France (MaaT013)

Available
  • Acute Graft Versus Host Disease in Intestine
  • Steroid Refractory GVHD
  • Amiens, France
  • +19 more
Jun 20, 2022

Steroid Resistant Acute GVHD Trial in Lyon (inolimomab)

Available
  • Steroid Resistant Acute Graft Versus Host Disease
  • inolimomab
  • Lyon, France
    ElsaLys Biotech
Sep 16, 2021

Chronic Graft-versus-host-disease Trial in United States (Itacitinib)

Recruiting
  • Chronic Graft-versus-host-disease
  • Denver, Colorado
  • +4 more
Jan 24, 2022